These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31524635)

  • 1. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
    Stern RM; Berliner N
    J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
    J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased mTOR activation in idiopathic multicentric Castleman disease.
    Arenas DJ; Floess K; Kobrin D; Pai RL; Srkalovic MB; Tamakloe MA; Rasheed R; Ziglar J; Khor J; Parente SAT; Pierson SK; Martinez D; Wertheim GB; Kambayashi T; Baur J; Teachey DT; Fajgenbaum DC
    Blood; 2020 May; 135(19):1673-1684. PubMed ID: 32206779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
    Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
    Ferrero S; Ragaini S
    J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
    Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
    J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology and targeted therapy in Castleman disease.
    Tsunoda S; Harada T; Kikushige Y; Kishimoto T; Yoshizaki K
    Expert Rev Clin Immunol; 2024 Sep; 20(9):1101-1112. PubMed ID: 38785062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate biomarkers for idiopathic multicentric Castleman disease.
    Sumiyoshi R; Koga T; Kawakami A
    J Clin Exp Hematop; 2022; 62(2):85-90. PubMed ID: 35768241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study.
    Liu YT; Gao YH; Zhao H; Zhang MY; Duan MH; Li J; Zhang L
    Ann Hematol; 2024 May; ():. PubMed ID: 38691144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
    Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
    Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
    Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
    Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
    Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
    Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
    Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
    Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
    Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).
    Koga T; Takemori S; Hagimori N; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Dec; 99(50):e23291. PubMed ID: 33327255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.
    Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C
    Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.